Edwards Lifesciences Corp (EW) Director Sells $1,466,880.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) Director William J. Phd Link sold 12,000 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $122.24, for a total transaction of $1,466,880.00. Following the completion of the transaction, the director now directly owns 24,596 shares of the company’s stock, valued at approximately $3,006,615.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Corp (EW) opened at $130.21 on Thursday. Edwards Lifesciences Corp has a 52 week low of $89.20 and a 52 week high of $138.48. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $27,560.00, a P/E ratio of 45.21, a PEG ratio of 1.87 and a beta of 0.63.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The company had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The firm’s revenue was up 15.7% compared to the same quarter last year. analysts expect that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.

Edwards Lifesciences declared that its board has initiated a stock buyback plan on Thursday, December 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

A number of research firms have recently commented on EW. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Barclays increased their target price on shares of Edwards Lifesciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. JMP Securities increased their target price on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, February 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $155.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $162.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $141.15.

Institutional investors have recently added to or reduced their stakes in the company. Cerebellum GP LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $128,000. Resources Investment Advisors Inc. increased its position in Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares during the period. Exane Derivatives increased its position in Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $140,000. Finally, Dupont Capital Management Corp acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at approximately $142,000. 81.11% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/02/15/edwards-lifesciences-corp-ew-director-sells-1466880-00-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply